Recombinant Human IGF-I/IGF-1, Animal-Free Protein
R&D Systems, part of Bio-Techne | Catalog # AFL291
Intended for preclinical researchers who may transition to GMP IGF-I/IGF-1 for their clinical work
Key Product Details
Learn more about Animal-Free Recombinant Proteins
Product Specifications
Source
E. coli-derived human IGF-I/IGF-1 protein
Gly49-Ala118
Produced using non-animal reagents in an animal-free laboratory.
Gly49-Ala118
Produced using non-animal reagents in an animal-free laboratory.
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Gly49
Predicted Molecular Mass
7.6 kDa
Activity
Measured in a serum-free cell proliferation assay using MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.
The ED50 for this effect is 0.3-1.5 ng/mL.
The specific activity of recombinant human IGF-I/IGF-1 is >1000 IU/mg, which is calibrated against the human IGF-I/IGF-1 WHO International Standard (NIBSC code: 91/554).
The ED50 for this effect is 0.3-1.5 ng/mL.
The specific activity of recombinant human IGF-I/IGF-1 is >1000 IU/mg, which is calibrated against the human IGF-I/IGF-1 WHO International Standard (NIBSC code: 91/554).
Formulation, Preparation and Storage
AFL291
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 0.2 mg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IGF-I/IGF-1
References
- Philippou, A. et al. (2007) In Vivo 21:45.
- Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
- Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
- Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
- Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
- Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
- Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
- Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
- LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
- Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.
Long Name
Insulin-like Growth Factor I/Insulin-like Growth Factor 1
Alternate Names
IGF-1, IGF1, IGFI, Somatomedin A, Somatomedin C
Gene Symbol
IGF1
UniProt
Additional IGF-I/IGF-1 Products
Product Documents for Recombinant Human IGF-I/IGF-1, Animal-Free Protein
Manufacturing Specifications
Animal-Free Manufacturing ConditionsOur dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.
Production
- All molecular biology procedures use animal-free media and dedicated labware.
- Dedicated fermentors are utilized in committed animal-free areas.
Purification
- Protein purification columns are animal-free.
- Bulk proteins are filtered using animal-free filters.
- Purified proteins are stored in animal-free containers in a dedicated cold storage room.
- Low Endotoxin Level.
- No impairment of biological activity.
- High quality product obtained under stringent conditions.
- For ex vivo research or bioproduction, additional documentation can be provided.
Product Specific Notices for Recombinant Human IGF-I/IGF-1, Animal-Free Protein
For research use or further manufacturing only
Loading...
Loading...
Loading...